louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03232255: Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity
Official title: Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dentin Sensitivity
Lead sponsor: InQpharm Group
Sponsor class: INDUSTRY
First posted: 2017-07-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the benefit and tolerability of a Mouthrinse (IQP-OLP-101) in the treatment of dentine hypersensitivity.


Eligibility criteria: Inclusion Criteria:

1. At least one hypersensitive tooth in everyday life after PAV 1 in-office visit
2. At least one hypersensitive tooth in everyday life with a regular pain perception of at least 2 times per week after PAV 1 visit
3. At least one tooth with dentine hypersensitivity to air stimulation → VAS ≥ 40mm at study entry
4. Any sensitive tooth showing exposure of cervical dentine (gum recession) and no acute signs of caries on the exposed root
5. For subjects entering the study at stage PAR-control: good healing of the periodontal surgery site, cause of pain must not be the result of the periodontal surgery
6. Age ≥ 18 years and ≤ 75 years
7. Willing and able to attend the on-study visits
8. Willing and able to understand and to follow the study procedures and instructions
9. Good oral hygiene throughout the study
10. Written informed consent before participation in the study
11. Subjects have undergone dental hygiene treatment immediately prior to study inclusion (except subjects entering the study at stage PAR-control)

Exclusion Criteria:

1. Hypersensitivity only due to sweets
2. Allergic reactions to any ingredients of InQpharm Mouthrinse e.g. chlorhexidine, zinc lactate
3. Professional desensitizing therapy during the previous 3 months; GLUMA (glutaraldehyde/hydroxyethyl methacrylate) desensitizer application within 6 months
4. Chronic systemic anti-inflammatory and analgesic medications
5. Systemic disorders causing or predisposing to dental (e.g. dry mouth, reflux, eating disorders, etc.)
6. Teeth or supporting structures with any other painful pathology or defect
7. Subject with poor health conditions
8. Concurrent participation in another clinical trial
9. Pregnant or lactating women

Primary outcomes:
measure: Change in dentine hypersensitivity
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fellbach
country: Germany
facility: Praxisklinik ORS
Study officials:
References:
Clinical trial NCT02915055: NSAID vs. Narcotics
Official title: Multimodal Analgesia With NSAID vs. Narcotics Alone for Post-operative Meniscectomy: A Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multimodal Analgesia
Nonsteroidal Anti-inflammatory Drugs
Keywords: Analgesic efficacy
knee arthroplasty
Opioid consumption
Pain Medicine
Narcotics
Multimodal Analgesia
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2016-09-26
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients indicated for isolated arthroscopic meniscectomy will be identified from the operating room schedules of orthopaedic surgeons participating in the study. And a review of patients' medications and past medical histories will be performed based on their electronic medical records to identify any current pain medications or exclusion criteria.

Brief summary: This will be a single-center, prospective observational study. The study will compare post-operative pain scores and narcotic consumption between two groups of patients - one cohort will receive ibuprofen (Motrin) and Percocet (to be used as needed) while the other cohort will receive only Percocet. Both pain management options are considered to be standard of care.

The primary objective of the study is to compare patients' reported pain and narcotic use following meniscectomy, and determine if NSAIDs can provide adequate pain relief.


Eligibility criteria: Inclusion Criteria:

* Must be at least 18 years of age
* ASA class I-II
* Patients scheduled for meniscectomy

Exclusion Criteria:

* Contraindication to ibuprofen or oxycodone/acetaminophen (e.g. hypersensitivity, history of GI or bleeding disorder)
* Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)
* Younger than 18 years of age or older than 65
* Any patient considered a vulnerable subject
* Patients on pain medication prior to surgery

Primary outcomes:
measure: Visual analogue scale (VAS) score
timeFrame: 4 Hours
measure: Pain Verbal Rating Scale
timeFrame: 4 Hours
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: New York University Medical School
name: Kirk Campbell, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06575855: Comparative Effectivenes of IASTM and MET on Post Operative Elbow Stiffness
Official title: Comparative Effectiveness of Instrument Assisted Soft Tissue Mobilization IASTM and Muscle Energy Technique MET on Post Operative Elbow Stiffness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Elbow Stiffness
Keywords: Post operative elbow stiffness, MET, IASTM
Lead sponsor: University of Faisalabad
Sponsor class: OTHER
Collaborators: name: University of Sargodha
First posted: 2024-08-28
Enrollment: 28
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 28 participants divided in to two groups, Group A and Group B
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study is basically for the evaluation of comparative effectiveness of instrument assisted soft tissue mobilization IASTM and muscle energy technique MET on Post operative , Randomized clinical trial .

Detailed description: In this study 28 participants including, which is further devided into two groups,14 in each group which is named as Group A,and Group B respectively.these groups are randomly allocated and give them intervention.which is instrument assisted soft tissue mobilization IASTM given to Group A and muscle energy technique MET given to Group B,then compare the effectiveness of both groups on Post operative elbow stiffness, duration of protocol is basically for 2,3 weeks depending upon patient condition and present situation.

Eligibility criteria: Inclusion Criteria:

* gender both Age:30 to 50 years Who fullfil concent form

Exclusion Criteria:

* other than inclusion criteria

Primary outcomes:
measure: VAS and goniometer
timeFrame: 4 months
Secondary outcomes:
measure: DASH questionaire
timeFrame: 4 months
Other outcomes:
Locations:
city: Faisalābad
country: Pakistan
facility: Nayyab Goher
state: Punjab
Study officials:
References:
Clinical trial NCT01911455: Study of Acamprosate in Fragile x Syndrome
Official title: Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Fragile X Syndrome
Keywords: Fragile X Syndrome
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
Collaborators: name: Rush University Medical Center
First posted: 2013-07-30
Enrollment: 46
Sex: ALL
Minimum age (years): 5
Maximum age (years): 23
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).

Detailed description: Each subject with FXS will receive 10 weeks of blinded treatment with acamprosate or matching placebo. After completion of the double-blind phase, all subjects will have an opportunity to receive acamprosate as part of the study procedures for 16 weeks.

Eligibility criteria: Inclusion Criteria:

* Diagnostic confirmation of full mutation FXS
* Age ≥5 years and \<23 years
* General good health as determined by physical exam, medical history and laboratory work up.

Exclusion Criteria:

* Use of more than two psychotropic medications (medications affecting behavior).
* Unstable dosing of any psychotropic medication (medication affecting behavior)
* Problems with kidney functioning
* Unstable seizure disorder
* Change in any anti-convulsant drug dosing in the 60 days prior to study entry
* Prior adequate treatment trial with acamprosate as determined by the study doctor
* Pregnant or lactating females

Primary outcomes:
measure: Aberrant Behavior Checklist-Social Withdrawal subscale
timeFrame: Change from baseline to week 10
Secondary outcomes:
measure: Clinical Global Impressions- Improvement (CGI-I)
timeFrame: week 10
measure: Aberrant Behavior Checklist- Hyperactivity (ABC-H)
timeFrame: Change from baseline to week 10
measure: Aberrant Behavior Checklist-Social Avoidance (ABC-SA)
timeFrame: Change from baseline to week 10
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
Study officials:
affiliation: Children's Hospital Medical Center, Cincinnati
name: Craig Erickson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Rush University Medical Center
name: Elizabeth Berry-Kravis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01182155: Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation
Official title: Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation: A Feasibility Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Keywords: Lung Cancer Non-Small Cell Cancer (NSCLC)
Lung Cancer Small Cell Lung Cancer (SCLC)
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2010-08-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with lung tumors who are undergoing radiation therapy

Brief summary: Patients treated with radiation therapy for lung tumors can experience inflammation after treatment. This study hopes to evaluate the use of breath analysis to evaluate changes in the composition of exhaled breath in patients undergoing radiotherapy. If changes can be detected, this may ultimately serve as biomarkers for identifying patients at highest risk for radiation-induced lung injury (radiation pneumonitis).


Eligibility criteria: Inclusion Criteria:

* Diagnosis of any type of lung tumor
* Medical recommendation (independent of the study) that the patient undergo thoracic radiation therapy. Radiation therapy may be either fractionated or hypofractionated (i.e. radiosurgery)
* Age \>= 18 years old
* Any gender and any ethnic background will be recruited
* Capable of giving written informed consent

Exclusion Criteria:

* Inability of giving written informed consent
* Pregnancy or breast-feeding

Primary outcomes:
measure: Pre and post-radiation FeNO (fraction of exhaled nitric oxide) measurements
timeFrame: Every 3 months for 1 year
Secondary outcomes:
measure: Pre and post-radiation CO (carbon monoxide), CO2 (carbon dioxide), and N2O (nitrous oxide) measurements and feasibility as the fraction of patients unable to give a breath sample. Adverse events are not expected but any that appear related to the breath
timeFrame: 1 yr
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Dr. Maximilian Diehn MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02493855: Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
Official title: An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C
Hepatitis C (HCV)
Hepatitis C Genotype 1a
Keywords: Treatment naive
HCV
Interferon free
Hepatitis C Genotype 1a
Chronic Hepatitis C
Hepatitis C
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2015-07-10
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.


Eligibility criteria: Inclusion Criteria:

1. Screening laboratory result indicating HCV genotype 1 (GT1) a infection.
2. Chronic HCV infection.
3. Subjects must be non-cirrhotic.
4. Subjects must be able to understand and adhere to the study visit schedule and all protocol requirements as well as voluntarily sign and date an institutional review board (IRB) approved informed consent.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding.
2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) positive immunoassay.
3. Clinically significant abnormalities or co-morbidities, other than HCV infection, that make the subject unsuitable for this study or treatment.
4. Current enrollment in another interventional clinical study. Previous use of any HCV treatments including pegylated interferon (pegIFN), ribavirin, or any direct acting antiviral agent, either investigational or approved, for HCV including protease inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or nonstructural viral protein 5A (NS5A) inhibitors.
5. History or solid organ transplant.
6. Screening laboratory analysis that shows abnormal results.

Primary outcomes:
measure: Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment
timeFrame: From Week 0 to Week 2
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: Emily Dumas, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00647114: A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Official title: A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients With Cancer Expressing HER-2 and/or CEA
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Keywords: Cancers expressing HER-2 and/or CEA
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-03-31
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.

Detailed description: The optional followup period for this study is 1 year after the last vaccination.

Eligibility criteria: Inclusion Criteria:

* Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
* Patient must not be pregnant 3 days prior to enrollment

Exclusion Criteria:

* Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
* Patient has had their spleen removed or has a history of autoimmune disorders
* Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
* Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
* Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
* Patient has a known history of Hepatitis B or C
* Patient has received a vaccine for any disease or condition within one month of enrollment
* Patient has a primary central nervous system tumor.

Primary outcomes:
measure: To determine the safety and tolerability of V930/V932 followed by EP in cancer patients
timeFrame: Week 22
Secondary outcomes:
measure: To determine whether V930/V932 can elicit HER-2 specific and CEA specific immune responses measured using an ELISPOT assay
timeFrame: Week 22
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013 Mar 8;11:62. doi: 10.1186/1479-5876-11-62.
Clinical trial NCT04491214: Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19)
Official title: Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Follow up
Rehabilitation
Keywords: SARS-CoV-2
Follow up
Intensive care unit
Cohort
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-07-29
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with severe SARS-Cov-2 hospitalized in intensive care.

Brief summary: Patients affected by new coronavirus infectious disease (COVID) were mostly hospitalized in ICU. This infection seems to cause widespread organ injury (i.e acute renal injury, neurological disorders, pulmonary embolism,...). It is therefore necessary to provide a framework for the follow up of patients. Moreover SARS-CoV-2 infection consequences remain unknow at this time. Study hypothesis is that COVID alters determining factors (physical or psychological) of quality of life after ICU hospitalisation. The aim of the study is to assess quality of life 3 months after ICU hospitalization.

Secondary purposes of the study are 1) assessment of quality of life 6 months and the evolution between the third and the sixth months after ICU hospitalization 2) description patients care after 3 and 6 months ICU left and their clinical status 3) convening and providing a "platform" within several physicians (neurologist, biologist, pneumologist...) will be able to follow up patients and perform complementary investigations according to patients injuries.


Eligibility criteria: Inclusion criteria:

* Subject male or female ≥ 18 years old
* Patient hospitalized in the anesthesia-resuscitation department of the NHC for COVID-19 from March 1, 2020.
* Patient (or his legal representative) having given his consent for the use of his data for the purposes of this research.

exclusion criteria:

* Subject not hospitalized in intensive care
* Patient's refusal to participate in the study
* Inability to give informed information to the subject (subject in an emergency, difficulty understanding the subject, etc.)
* Subject under low protection

Primary outcomes:
measure: assess quality of life after severe COVID infection
timeFrame: measured at 3 months after ICU left.
Secondary outcomes:
measure: Quality of life and Clinical status
timeFrame: measured at 3 and 6 months after ICU left.
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Hôpitaux Universitaires de Strasbourg (Nouvel Hôpital Civil)
Study officials:
References:
Clinical trial NCT06927414: Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents
Official title: Exploratory Study on the Effectiveness and Safety of Light Diffraction Frame Glasses in Preventing and Controlling Myopia in Children and Adolescents
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Myopia Progressing
Lead sponsor: Shanghai Eye Disease Prevention and Treatment Center
Sponsor class: OTHER
First posted: 2025-04-15
Enrollment: 40
Sex: ALL
Minimum age (years): 6
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate the effectiveness of lenses with light diffraction glasses in controlling the progression of myopia in children and adolescents, and to explore the feasibility of effective design, and apply personalized frame lenses for myopia prevention and control.


Eligibility criteria: Inclusion Criteria:

1. Age: 6-8 years old;
2. After using 1% cyclohexanone hydrochloride eye drops (Saifeijie) for ciliary muscle paralysis, binocular spherical power were within 0.00D\~-1.75D, binocular cylinder power ≤ 1.50D, the anisometropia is less than 1.50D, the progression of myopia in the past year is greater than 0.5D, the best corrected far vision is at least 4.8, and the near vision is at least 5.0;
3. Within 6 months, the myopia prevention and control methods such as multifocal glasses, orthokeratology, defocusing flexible glasses, progressive glasses, atropine eye drops, red light and acupuncture and moxibustion treatment were not used;
4. The subject has a willingness to receive treatment and an informed consent form is signed by their legal guardian.

Exclusion Criteria:

1. Diagnosed constant strabismus;
2. Diagnosed pathological myopia;
3. Other congenital eye diseases;
4. Researchers believe that the patients have other reasons that are not suitable for inclusion in the project.

Primary outcomes:
measure: Subjective refraction equivalent spherical
timeFrame: 3 months
Secondary outcomes:
measure: Axial length
timeFrame: 3 months
measure: Choroidal thickness
timeFrame: 3 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Eye Diseases Prevention &amp;Treatment Center/ Shanghai Eye Hospital, School of Medicine, Tongji University
state: Shanghai
Study officials:
References: